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Summary Murine monoclonal antibody CF511, raised against human ovarian clear cell carcinoma, detects a
glycoprotein (Mr 600 kDa) called CF511 antigen which is elevated in the serum of many patients with ovarian
carcinoma. A competitive enzyme-linked immunosorbent assay was developed to detect CF511 antigen in
human serum and used to detected CF511 antigen in subjects with ovarian carcinoma and other diseases. No
raised levels (<18 unit (U) ml-') of the antigen were found in the serum of 220 normal individuals or of
patients with germ cell tumours (n = 6), granulosa theca cell tumour (n = 1), gastric carcinomas (n = 10) and
colo-rectal carcinomas (n = 8). Raised serum levels of CF511 antigen were found in 6/46 patients (13.0%) with
benign gynaecological tumours (including endometriosis or ovarian cyst), in 5/7 patients (71.4%) with breast
carcinoma and 16/21 (76.2%) lung carcinoma patients. In patients with ovarian carcinoma, 42.3% (11/26) of
stage I and II, and 96.0% (24/25) of stage III and IV had levels of > 18 U ml-'. In all patients with serial
determination of CF511 antigen levels before and after the surgery, the levels of antigen correlated with the
clinical course of disease. Determination of CF511 antigen levels may be useful for detection of ovarian
carcinoma as well as lung and breast carcinomas and for monitoring progress of disease and response to
therapy.
Ovarian carcinoma is the most lethal of all gynaecological
carcinomas. However, the disease is curable if diagnosed at
an early stage, and early detection is associated with a better
prognosis (Petterson, 1985). It is therefore important to
develop new methods for the early detection of the diseases.
Among many tumour markers developed for serum diagnosis
of ovarian carcinoma, CA125 has been known as the most
useful marker (Zanaboni et al., 1987). However, the false
positive rate of CA125 in sera from patients with endometri-
osis has been rather high (Niloff et al., 1984; Takahashi et
al., 1986).
We have developed a serum test for the detection of
ovarian carcinoma based on the use of a monoclonal
antibody CF511 (Ohkawa et al., 1989). This antibody was
generated by immunisation with human foetal tissue extract
from early first trimester, followed by booster injection of a
human ovarian carcinoma cell line and reacts with 87.1% of
ovarian carcinomas by immunoperoxidase technique, but has
a limited reactivity with other normal tissues. The mono-
clonal antibody CF511 defined antigen (CF511 antigen),
600 kDa glycoprotein, was also detectable in sera from
patients with ovarian carcinoma.
The purpose of this study was to determine the serum
levels of CF511 antigen in normal population, patients with
ovarian carcinoma, benign gynaecological disease, and other
carcinoma and to assess the usefulness of these levels for
monitoring the disease with sensitive competitive enzyme-
linked immunosorbent assay (ELISA).
Materials and methods
Serum samples
Normal serum samples were obtained from healthy
volunteers in Jikei University Hospital and in Tokuyama
Soda Laboratory. Serum samples from patients with ovarian
carcinoma (serous, 24 cases; mucinous, 11; endometrioid, 4;
clear cell, 7; undifferentiated, 5) and other diseases were
obtained from Jikei University Hospital. The samples were
stored at - 80°C until use.
Competitive ELISA
CF511 antigen-rich fraction used in the competitive ELISA
was extracted from HAC 2 cells by 1 M urea in 10 mM
sodium phosphate, pH 7.0, 150 mM NaCl (PBS) for 20min
at 4°C (Kishi et al., 1980). The urea-extracted solution was
dialysed extensively against PBS. Protein was assayed by
Lowry et al. (1951). The antigen solution (1 lag ml-') coated
onto 96-well microtiter plates (Nunc, Denmark) at 4°C for
7 h. After washing the plates with PBS, the wells were treated
with 5% skimmed milk in 20 mM Tris HCl, pH 7.5, 0.5 M
NaCl (TBS) for 1 h at room temperature to block protein
binding sites. The 50 p1l of patient's serum (1/10 diluted with
1% bovine serum albumin in TBS) was preincubated with
the same volume of alkaline phosphatase-labelled CF5 1I
antibody (500 ng ml-') for 2 h at room temperature. Alkaline
phosphatase-labelled CF511 was prepared with purified
CF511 conjugated to calf intestinal alkaline phosphatase
(Boehringer Mannheim, Germany) using glutaraldehyde ac-
cording to the method previously reported by Schreier et al.
(1980). Fifty ftl of the incubation mixture was then put into
the antigen-coated wells and incubated further 17 h at 4°C.
After five repeated washing steps with 0.05% Tween 20 in
TBS, 100p1 of p-nitrophenylphosphate in 10mM diethanol-
amine, pH 9.5, 0.5 mM MgCI2 as a substrate was added and
the absorbance at 405 nm was determined after 30 min of
colour development with a microplate reader (MPRA4,
TOSOH, Japan). The results were expressed in terms of a
unit (U) ml-' calculated from the titration curve of the
standard antigen. One pg ml-' of partially purified antigen
measured by Lowry's method (Lowry et al., 1951) was
defined as 100 U ml-' of CF511 antigen. A sample was
considered to be positive when the value was beyond the
normal range, namely, the mean plus two standard devia-
tions, for control samples from healthy volunteers. CA125
and CA72-4 were determined using the commercially
available immunoassay kits (Centocor, Malvern, PA, USA).
Results
Establishment ofcompetitive ELISA
A typical standard curve for CF511 antigen assay is shown in
Figure 1. The mean intra-assay coefficient of variation
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Figure 1 Standard curve for CF511 antigen. Points: Mean of
triplicate determinations. Bars: Standard deviation. (See
Materials and methods for details).
Figure 2 Levels of CF511 antigen in the serum of patients with
ovarian carcinomas and benign gynaecological diseases and heal-
thy individuals. The arbitary cut-off value was determined by
preliminary tests of sera from healthy individuals to establish a
normal range as described in Materials and methods. Other
ovarian tumours containing either germ cell or sexcord mesenchy-
mal cell elements.
obtained by testing the standard antigen was 7.5% and the
inter-assay coefficient of variation calculated from four
different assays for the same antigen was 10.0%.
CF511 antigen levels in serum
Normal individuals A distribution of CF511 antigen levels
seen in normal samples is shown in Figure 2. The cut-off
value was set at 18 U ml- ' based on the normal range
(mean + 2 s.d. = 7.9 + 4.9 x 2 = 17.7) for control samples
from 220 normal individuals. No case was positive in normal
individuals.
Ovarian carcinoma Sixty-nine per cent of sera from patients
showed elevated levels of antigen (Figure 2). As shown in
Figure 3, moderately raised CF511 antigen levels were
detected in patients with stage I (Petterson, 1985)
(22.3 ± 28.6) and stage 11 (19.0 ± 13.1) ovarian carcinoma
and, using the cut-off value of 18 U ml-', 45.0% (9/20) of
stage I and 33.3% (2/6) of stage II had elevated levels.
Higher levels of CF511 antigen were noted in patients with
advanced stages (stage III; 36.5 ± 20.8, stage IV; 44.6 ± 18.2),
and 95.0% (19/20) and 100% (5/5) of patients had elevated
levels of the antigen, respectively. A close relationship
between CF511 antigen level and clinical stage was observed,
suggesting an association between antigen level and tumour
burden, but no relationship was noted between CF511 anti-
gen level and histological type of carcinoma (Figure 4).
Benign gynaecological diseases Low but significant elevation
of CF511 antigen levels were found in six of 46 (13%)
patients with benign gynaecological diseases, including 0/7
ovarian cysts and 6/39 uterine fibroids with or without
endometriosis (Figure 2).
Other malignant tumours Elevated levels of CF511 antigen
were present in five of seven patients with breast carcinoma,
16 of 21 with lung carcinoma, but this did not occur in the
patients with either gastric carcinoma (0/10) or colo-rectal
carcinoma (0/8). No elevated levels of the antigen were
detected in patients with germ cell or sex cord mesenchymal
cell tumours (Figure 2).
Correlation of CFSJJ antigen levels and clinical status for
monitoring the progress of ovarian carcinoma In 13 patients
with ovarian carcinoma with various clinical stages, CF511
antigen levels were determined serially before and after the
surgery. In all patients the CF511 antigen level fell within
stage (n = 20)
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Figure 3 Levels of CF5 1I antigen in the serum of patients with
Stage I, II, III and IV ovarian carcinoma. Each point represents
an individual patient.
serous (n = 24)
mucinous (n 11)
endometrioid (n = 4)
clear cell (n = 7)
undifferentiated (n = 5)
I
I
I
I
I
0 000 SW or* go : 0 *
I
I
I
I
139
I
1*
50 1oo
CF511 Antigen (unit ml-')
Figure 4 Levels of CF511 antigen in the serum of patients with
ovarian carcinoma of various types of histology (serous,
mucinous, endometrioid, clear cell, and undifferentiated). Each
point represents an individual patient.
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7 days following the operation (Figure 5). A representative
example is described. The patient with mucinous cystadeno-
carcinoma, stage IV, was monitored for CF511 antigen and
CA125 level over 8 months (Figure 6). After surgery followed
by cytotoxic chemotherapy, her disease was arrested and had
a probable partial response for a period of 4 months. During
that time, there was a corresponding fall in CF511 antigen
level from 55 U ml-' to 12 U ml-'. However, during the
following 1 month, the CF511 antigen levels rose again to
19 U ml-' without elevation of CA125 despite the disease
remaining stable and it was not until 2 months later that
disease progression was first clinically detected by CT scan.
The antigen levels continued to rise for 3 months to
75 U ml-'.
Correlation between serum CF511 antigen levels and CA72-4
or CA125 levels Serum levels of CF511 antigen, CA72-4
and CA125 were assayed simultaneously in 22 patients with
ovarian carcinomas and nine patients with pathologically
confirmed advanced pelvic endometriosis with uterine
fibroids (these cases contained in 39 cases of uterine fibroids
with endometriosis). There was no significant correlation was
among them in ovarian carcinoma patients. In endometriosis
the positive rates of CA125 were moderately high (6/9) com-
pared with those of CF511 antigen (1/9) (Figure 7).
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Figure 7 The correlation of CF511 antigen (x-axis) and CA72-4
or CA125 (Y-axis). Symbols: serous *; mucinous A; endo-
metrioid V; clear cell *; undifferentiated 0; endometriosis 0.
Discussion
After
Figure 5 Changes of CF511 antigen levels in patients with
ovarian carcinoma (serous U; mucinous A; endometrioid V;
clear cell *; and undifferentiated 0) before and 7 day-after the
cytoreductive surgery.
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Figure 6 Serial monitoring the clinical course of patient
(mucinous cystadenocarcinoma stage IV) with CF511 antigen
levels and CA125 levels. Changes of the marker levels in the
patient following initiation of cytoreductive surgery (arrow) fol-
lowed by cytotoxic chemotherapy (0).
A serum assay for ovarian carcinoma has been described,
based on the detection of a CF511 antigen, a high molecular
weight 600 kDa glycoprotein without crossreacting to
CA125, using monoclonal antibody CF511. The assay was
formulated using a standard dilution of purified monoclonal
antibody, as purified antigen was unavailable. A competitive
ELISA was developed and the assay has shown that ele-
vated serum levels of CF511 antigen are present in most
patients with advanced ovarian carcinoma, however lower
but elevated antigen levels are also found in the sera from
one third of the patients with early stage diseases. The
arbitarily chosen cut-off values of > 18 U ml-' resulted in a
specificity of 3.6% false positives and a sensitivity of 68.6%
true positives. As the immune reaction between CF511
antigen and antibody was not inhibited by the addition of
commercially available well-recognised antigen (CA125,
CAl9-9, CA15-3, Du-PAN-2, SLX and CSLEX) (Ohkawa et
al., 1989), CF511 antigen is different from these antigens.
The CF511 reactivity is distinguished from that of CA72-4
(Thor et al., 1986) and no significant correlation between
CA125 and CF511 antigen levels was also demonstrated
(Figure 7). Furthermore CF511 assay has a low positive
frequency in benign ovarian cyst (0%) and endometriosis
(11%). High frequency of false-positive rate in endometriosis
in CA125 (70-90%) (Takahashi et al., 1986) is a disadvant-
age of CA125 in the diagnosis of ovarian carcinomas. These
studies demonstrate the clinical advantage of combination
assay with CF511 and other markers in the diagnosis and
monitoring of ovarian carcinomas. CF511 antigen levels were
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also elevated in the sera from patients with breast carcinoma
as well as lung carcinoma tested. In this respect, CF511 assay
may be clinically useful for cancer detection and more exten-
sive studies are necessary to confirm the usefulness of this
assay.
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